Gallbladder Cancer - Pipeline Review, H2 2017

Publisher Name :
Date: 30-Nov-2017
No. of pages: 179
Inquire Before Buying

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2017, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.

Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gallbladder Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 14, 4 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gallbladder Cancer (Oncology).

  • The pipeline guide reviews pipeline therapeutics for Gallbladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Gallbladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Gallbladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Gallbladder Cancer (Oncology)


Reasons to buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Gallbladder Cancer (Oncology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Gallbladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Gallbladder Cancer - Pipeline Review, H2 2017

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Gallbladder Cancer - Overview 7
Gallbladder Cancer - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Gallbladder Cancer - Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 18
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Gallbladder Cancer - Companies Involved in Therapeutics Development 25
4SC AG 25
Advenchen Laboratories LLC 25
Array BioPharma Inc 25
Aslan Pharmaceuticals Pte Ltd 26
Bayer AG 26
BeiGene Ltd 27
Eli Lilly and Co 27
Halozyme Therapeutics Inc 28
Hutchison MediPharma Ltd 28
Ipsen SA 29
Kringle Pharma Inc 29
Leap Therapeutics Inc 30
MedImmune LLC 30
Molecular Templates Inc 30
Novartis AG 31
NuCana Plc 31
OncoTherapy Science Inc 32
VasGene Therapeutics Inc 32
Gallbladder Cancer - Drug Profiles 33
apatinib mesylate - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
BGBA-317 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
binimetinib - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
copanlisib hydrochloride - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
DKN-01 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
durvalumab - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
evofosfamide - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
HMPL-012 - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
irinotecan hydrochloride - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
merestinib - Drug Profile 116
Product Description 116
Mechanism Of Action 116
R&D Progress 116
NK-4 - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
NUC-1031 - Drug Profile 120
Product Description 120
Mechanism Of Action 120
R&D Progress 120
OCVC-01 - Drug Profile 123
Product Description 123
Mechanism Of Action 123
R&D Progress 123
pazopanib hydrochloride - Drug Profile 124
Product Description 124
Mechanism Of Action 124
R&D Progress 124
PEGPH-20 - Drug Profile 133
Product Description 133
Mechanism Of Action 133
R&D Progress 133
ramucirumab - Drug Profile 143
Product Description 143
Mechanism Of Action 143
R&D Progress 143
resminostat - Drug Profile 155
Product Description 155
Mechanism Of Action 155
R&D Progress 155
trametinib dimethyl sulfoxide - Drug Profile 165
Product Description 165
Mechanism Of Action 165
R&D Progress 165
varlitinib - Drug Profile 170
Product Description 170
Mechanism Of Action 170
R&D Progress 170
Vas-01 - Drug Profile 175
Product Description 175
Mechanism Of Action 175
R&D Progress 175
Gallbladder Cancer - Dormant Projects 177
Appendix 178
Methodology 178
Coverage 178
Secondary Research 178
Primary Research 178
Expert Panel Validation 178
Contact Us 178
Disclaimer 179

List of Tables

Number of Products under Development for Gallbladder Cancer, H2 2017 8
Number of Products under Development by Companies, H2 2017 10
Number of Products under Development by Universities/Institutes, H2 2017 11
Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13
Products under Development by Universities/Institutes, H2 2017 14
Number of Products by Stage and Target, H2 2017 16
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 17
Number of Products by Stage and Mechanism of Action, H2 2017 19
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 20
Number of Products by Stage and Route of Administration, H2 2017 22
Number of Products by Stage and Molecule Type, H2 2017 24
Gallbladder Cancer - Pipeline by 4SC AG, H2 2017 25
Gallbladder Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017 25
Gallbladder Cancer - Pipeline by Array BioPharma Inc, H2 2017 26
Gallbladder Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017 26
Gallbladder Cancer - Pipeline by Bayer AG, H2 2017 27
Gallbladder Cancer - Pipeline by BeiGene Ltd, H2 2017 27
Gallbladder Cancer - Pipeline by Eli Lilly and Co, H2 2017 28
Gallbladder Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2017 28
Gallbladder Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2017 29
Gallbladder Cancer - Pipeline by Ipsen SA, H2 2017 29
Gallbladder Cancer - Pipeline by Kringle Pharma Inc, H2 2017 29
Gallbladder Cancer - Pipeline by Leap Therapeutics Inc, H2 2017 30
Gallbladder Cancer - Pipeline by MedImmune LLC, H2 2017 30
Gallbladder Cancer - Pipeline by Molecular Templates Inc, H2 2017 31
Gallbladder Cancer - Pipeline by Novartis AG, H2 2017 31
Gallbladder Cancer - Pipeline by NuCana Plc, H2 2017 31
Gallbladder Cancer - Pipeline by OncoTherapy Science Inc, H2 2017 32
Gallbladder Cancer - Pipeline by VasGene Therapeutics Inc, H2 2017 32
Gallbladder Cancer - Dormant Projects, H2 2017 177

List of Figures

Number of Products under Development for Gallbladder Cancer, H2 2017 8
Number of Products under Development by Companies, H2 2017 9
Number of Products by Top 10 Targets, H2 2017 15
Number of Products by Stage and Top 10 Targets, H2 2017 15
Number of Products by Top 10 Mechanism of Actions, H2 2017 18
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 18
Number of Products by Routes of Administration, H2 2017 21
Number of Products by Stage and Routes of Administration, H2 2017 21
Number of Products by Molecule Types, H2 2017 23
Number of Products by Stage and Molecule Types, H2 2017 23

  • Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 27-Jun-2018        Price: US 3480 Onwards        Pages: 150
    Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect. Cancer stem cells (CSCs) are cancer cells tha......
  • Pancreatic Cancer - Pipeline Review, H1 2018
    Published: 22-Jun-2018        Price: US 2500 Onwards        Pages: 2509
    Pancreatic Cancer - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H1 2018, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may ......
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2018
    Published: 22-Jun-2018        Price: US 2000 Onwards        Pages: 853
    Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2018, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline landscape. Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss ......
  • Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018
    Published: 22-Jun-2018        Price: US 2500 Onwards        Pages: 1759
    Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape. Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells wit......
  • Global Non-small Cell Lung Cancer Therapeutics Sales Market Report 2018
    Published: 18-Jun-2018        Price: US 4000 Onwards        Pages: 105
    This report studies the global Non-small Cell Lung Cancer Therapeutics market status and forecast, categorizes the global Non-small Cell Lung Cancer Therapeutics market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer othe......
  • Global Non-small Cell Lung Cancer Therapeutics Market Research Report 2018
    Published: 18-Jun-2018        Price: US 2900 Onwards        Pages: 94
    This report studies the global Non-small Cell Lung Cancer Therapeutics market status and forecast, categorizes the global Non-small Cell Lung Cancer Therapeutics market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC ......
  • Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size, Status and Forecast 2025
    Published: 13-Jun-2018        Price: US 3300 Onwards        Pages: 104
    This report studies the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market by companies, region, type and end-use industry. Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumo......
  • 2018-2023 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Report (Status and Outlook)
    Published: 06-Jun-2018        Price: US 4660 Onwards        Pages: 153
    In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market for 2018-2023. Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs ......
  • Global Cancer Gene Therapy Market Professional Survey Report 2018
    Published: 05-Jun-2018        Price: US 3500 Onwards        Pages: 120
    This report studies the global Cancer Gene Therapy market status and forecast, categorizes the global Cancer Gene Therapy market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The global Cancer Gene Therapy market is valued at xx million US$ in 2017 and is expected to reach xx milli......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs